ZR2 RDHAP
Phase 2Small molecule
ZR2 RDHAP is one of 12 small molecule programs targeting Immunochemotherapy. It is currently in Phase 2.
1
Indications
1
Total Trials
1
Active Trials
11
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
11 competitors in Immunochemotherapy
#DrugCompanyPhaseTrials
1Keytruda
Merck & Co.Phase 3
Immunotherapy
Bristol-Myers SquibbPhase 3
Tuoyi
SSun Yat-sen University
Phase 2
Platinol
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Phase 2
PD-1 Inhibitor
Johnson & JohnsonPhase 2
Paclitaxel-Albumin
SSunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
Phase 2
Pd-1inhibitor
SSun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Phase 3
Platinum Doublet
RegeneronPhase 2
R-IDARAM Plus Intrathecal Chemotherapy
NNavy General Hospital, Beijing
Phase 3
Adebrelimab Combined With DOS
TTang-Du Hospital
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for ZR2 RDHAP. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- ZZhejiang Cancer Hospital